

Dr. Schiepers was correct in pointing out the complexity of our imaging protocol. As opposed to Dr. Schiepers' imaging method, which included the prostate throughout the duration of the scan, our imaging protocol included both the prostate and the lower abdomen so as to detect potential metastatic disease. This protocol required that we move the patient back and forth between the 2 scanning positions, first scanning the pelvis and then the lower abdomen, each for 2 min at a time. This technique can create subtle misalignments and other quantitation issues due to altered decay corrections and the inability of the reconstruction software to reproduce accurate SUVs. However, the latter issue is minor and is related mostly to rounding-off errors in entering the injection time.

The most challenging part of the imaging protocol was that the first 6 min of the scan were acquired in list mode; thus, we reconstructed the data in time frames, with the last time frame truncating the time–activity curve at 6 min. The prostate was then moved out of the field of view for the first lower-abdomen scan and then back into the field of view for the next 2-min scan at about 12–15 min after injection. The use of these time frames necessarily causes a sampling gap between 6 min and 12–15 min that would help confirm either a true biphasic pattern or an artifact due to the complicated nature of the imaging protocol. Another potential issue is that the dose used (1,480 MBq) was substantially higher than that used in the Schiepers study (370 MBq), thus causing potential SUV nonlinearities at early acquisition times.

To determine whether there were high rate effects or whether the complicated imaging protocol would lead to an artificial biphasic uptake curve, during the review of the time–activity data, fresh volumes of interest were drawn on hot-spot lesions in the prostate and in muscle tissue as a reference. If an artificial biphasic uptake pattern had been generated by either the high activity or the imaging protocol, it should have shown up in both prostate lesion and muscle tissue time–activity curves. Neither subject 36 nor subject 28 showed a biphasic pattern in the muscle time–activity curve, thus raising the possibility that the biphasic pattern is real and reflects actual metabolic differences among prostate cancers that may be of importance.

Regardless of the presence or absence of this biphasic pattern in the time–activity curve, the main conclusion of our paper remains the same: ^{11}C -acetate does not do a very good job in distinguishing between malignant tumors and BPH lesions. Because this is the major determinant of whether an imaging tool for localized prostate cancer succeeds, ^{11}C -acetate would not seem to pass this test.

REFERENCES

1. Mena E, Turkbey B, Mani H, et al. ^{11}C -acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. *J Nucl Med.* 2012;53:538–545.

2. Schiepers C, Hoh CK, Nuyts J, et al. ^{11}C -acetate kinetics of prostate cancer. *J Nucl Med.* 2008;49:206–215.

Stephen Adler
Karen Kurdziel*
Liza Lindenberg
Peter Choyke
Esther Mena

*National Cancer Institute
10 Center Dr., Room B3B403
Bethesda, MD 20892
E-mail: kurdziel@mail.nih.gov

Published online Jan. 15, 2013.
DOI: 10.2967/jnumed.112.114454

The Timing of Pregnancy Testing in ^{131}I Therapy

TO THE EDITOR: In the publication of the SNMMI guideline on ^{131}I therapy (1), there appears a recommendation for a pregnancy test to be performed within 24 h of the administration of ^{131}I for women of reproductive age who cannot provide written documentation of a hysterectomy or bilateral salpingo-oophorectomy.

Some readers have raised the concern that if the pregnancy test is obtained some hours before the suggested 24-h limit and a false-negative result ensues, they would be liable for a lawsuit. We must emphasize that a guideline is not a regulation and has no force of law.

It is simply a fact that pregnancy tests are negative until implantation of the embryo, which occurs 7–10 d after fertilization. Therefore, a test performed 48 h before therapy will miss more pregnancies than one performed at 24 h or on the same day, and it seems unreasonable to take that chance.

At the University of Cincinnati Medical Center, we draw blood for a β -human chorionic gonadotropin study on the day of therapy, the results of which will be returned in 30 min. Meanwhile, the nuclear pharmacy will not deliver the prescribed activity for 90–120 min, so no one is inconvenienced, and the patient is protected to the best of our ability from being treated while pregnant.

REFERENCE

1. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with ^{131}I 3.0. *J Nucl Med.* 2012;53:1633–1651.

Edward B. Silberstein
University of Cincinnati Medical Center
234 Goodman St.
Room G026, Mont Reid Pavilion
Cincinnati, OH 45219
E-mail: edward.silberstein@uchealth.com

Published online Jan. 3, 2013
DOI: 10.2967/jnumed.112.115071